Transcatheter Valve Coverage Proposal Reflects Stricter Medicare Environment
This article was originally published in The Gray Sheet
Executive Summary
CMS’ proposed national coverage determination comes only three months after the approval and launch of Edwards Lifesciences’ Sapien, the first transcatheter aortic valve in the U.S. It restricts coverage to FDA-approved indications and includes a coverage-with-evidence-development provision.